Unapproved Longevity Gene Therapy Bypasses FDA via Overseas Clinics
A US company is set to offer an unapproved gene therapy targeting the anti-ageing protein klotho through overseas clinics, according to reports. The therapy instructs cells to produce more klotho, a protein associated with longevity and cellular health.
By operating outside US borders, the company aims to bypass FDA regulations that would otherwise require extensive clinical trials and approval before marketing the treatment domestically.
Gene therapies targeting klotho have been studied for their potential effects on ageing-related conditions, though the safety and efficacy of this particular commercial offering remains unverified by regulatory authorities.